Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamle...
FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs
On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.
3 Stocks Under $50 Smart Investors Should Buy Hand Over Fist
It is never too early to start your investment journey.
New Pfizer and Moderna Covid-19 vaccines approved by US
US regulators have approved a new series of updated and improved COVID-19 vaccines to target a resurgence of the virus as new strains emerge. Pfizer Inc (NYSE:PFE, ETR:PFE) and Moderna Inc (NASDAQ:...
Updated COVID-19 vaccines from Pfizer, Moderna approved by FDA
The Food and Drug Administration on Thursday gave Pfizer Inc. and Moderna Inc. approval for updated COVID-19 vaccines, as a summer wave of the virus is still rolling across the country.
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
NEW YORK and MAINZ, GERMANY, August 22, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has ap...
FDA approves updated Pfizer, Moderna Covid vaccines as virus surges; shots to be available within days
The Food and Drug Administration approved updated Covid vaccines from Pfizer and Moderna, putting the shots on track to reach most Americans in the coming days as the virus surges. The jabs target ...
Looking for $1500 in Safe Passive Income Each Year? Invest This Much in Pfizer.
24/7 Wall St. Insights Pfizer is one of the highest-yielding S&P 500 stocks.
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achie...
Is Pfizer Stock Ready to Bounce Back?
Pfizer's revenue grew on a year-over-year basis for the first time in a while. Though a recent acquisition helped, there were other factors that contributed.
Why Pfizer Stock Slumped on Friday
Its combination COVID-19/influenza vaccine fell short of one of its endpoints in a late-stage clinical trial. The U.S. pharmaceutical giant is developing the jab with its European partner BioNTech.
Pfizer Dividend Yield Pushes Past 6%
In trading on Friday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.85 on the day. Dividends ar...
Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints
Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combi...
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
NEW YORK and MAINZ, Germany, August 16, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to eva...
Related Companies